- Capital Cube•5 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•27 days agoCumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient Support
NASHVILLE, Tenn., Sept. 26, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), announced today that it has launched the U.S. promotion of Ethyol® (amifostine) for Injection, a hospital-based product used to treat oncology patients. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. Cumberland entered into an exclusive agreement with Clinigen Group plc to commercialize Ethyol in the United States earlier this year.
- PR Newswire•last month
NASHVILLE, Tenn., Sept. 14, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), today announced the initiation of a new Phase II clinical program of Portaban™ for patients with portal hypertension associated with liver disease. The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. Portaban™ is an oral formulation of ifetroban and the fourth development candidate in Cumberland's pipeline.
Cumberland Pharmaceuticals, Inc. (CPIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Ask||12.00 x 300|
|Day's Range||4.76 - 4.95|
|52wk Range||4.20 - 6.50|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-493.00|
|Avg Vol (3m)||11,850|
|Dividend & Yield||N/A (N/A)|